A 2-Part, Safety, Tolerability, and Pharmacokinetic Study of LY2775240 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs LY 2775240 (Primary) ; Apremilast
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 03 Nov 2017 Status changed from active, no longer recruiting to completed.
- 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.